α-Synuclein in CSF of patients with severe traumatic brain injury

Neurology

Volumn 80, Issue 18, 2013, Pages 1662-1668

  Mondello, Stefania ^a   Buki, Andras ^b   Italiano, Domenico ^c   Jeromin, Andreas ^a  

^a BANYAN BIOMARKERS INC   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLASGOW COMA SCALE; HUMAN; LUMBAR PUNCTURE; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRAUMATIC BRAIN INJURY;

ADULT; AGED; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; BRAIN INJURIES; CASE-CONTROL STUDIES; FEMALE; GLASGOW COMA SCALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84879072693     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182904d43     Document Type: Article

References (37)

1. Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KK. Blood-based diagnostics of traumatic brain injuries. Expert Rev Mol Diagn 2011;11:65-78.
2. Kochanek PM, Berger RP, Bayir H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care 2008;14:135-141.
3. Mondello S, Jeromin A, Buki A, et al. Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 2012;29:1096-1104.
4. Dash PK, Zhao J, Hergenroeder G, Moore AN. Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 2010;7:100-114.
5. Magnoni S, Brody DL. New perspectives on amyloid-beta dynamics after acute brain injury: moving between experimental approaches and studies in the human brain. Arch Neurol 2010;67:1068-1073.
6. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009;68:709-735.
7. Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma 2011;28:1783-1801.
8. Lee PC, Bordelon Y, Bronstein J, Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology 2012;79:2061-2066.
9. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-240.
10. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 2011;10:1015-1025.
11. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-1410.
12. Wilson JT, Pettigrew LE, Teasdale GM. Emotional and cognitive consequences of head injury in relation to the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry 2000;69:204-209.
13. Jones DJ, Runyan DK, Lewis T, et al. Trajectories of childhood sexual abuse and early adolescent HIV/AIDS risk behaviors: the role of other maltreatment, witnessed violence, and child gender. J Clin Child Adolesc Psychol 2010;39:667-680.
14. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociological Methods Res 2001;29:374-393.
15. Nagin D, Tremblay RE. Trajectories of boys' physical aggression, opposition, and hyperactivity on the path to physically violent and nonviolent juvenile delinquency. Child Dev 1999;70:1181-1196.
16. Berger RP, Bazaco MC, Wagner AK, Kochanek PM, Fabio A. Trajectory analysis of serum biomarker concentrations facilitates outcome prediction after pediatric traumatic and hypoxemic brain injury. Dev Neurosci 2010;32:396-405.
17. Wagner AK, Amin KB, Niyonkuru C, et al. CSF Bcl-2 and cytochrome C temporal profiles in outcome prediction for adults with severe TBI. J Cereb Blood Flow Metab 2011;31:1886-1896.
18. Larsen KE, Schmitz Y, Troyer MD, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006;26:11915-11922.
19. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006;52:33-38.
20. Clough RL, Dermentzaki G, Haritou M, Petsakou A, Stefanis L. Regulation of alpha-synuclein expression in cultured cortical neurons. J Neurochem 2011;117:275-285.
21. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-1772.
22. Reesink FE, Lemstra AW, Van Dijk KD, et al. CSF alphasynuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 2010;22:87-95.
23. Kasuga K, Tokutake T, Ishikawa A, et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010;81:608-610.
24. Mondello S, Linnet A, Buki A, et al. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 2012;70:666-675.
25. Mondello S, Robicsek SA, Gabrielli A, et al. alphaII-Spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma 2010;27:1203-1213.
26. Su E, Bell MJ, Wisniewski SR, et al. alpha-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci 2010;32:385-395.
27. Adou K, Johnston MV. Flow interface for charge-reduced electrospray of nanoparticle solutions. Anal Chem 2009;81:10186-10192.
28. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-6024.
29. Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced alpha-synuclein is secreted in a calciumdependent manner by exosomes and impacts neuronal survival. J Neurosci 2010;30:6838-6851.
30. Danzer KM, Ruf WP, Putcha P, et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 2011;25:326-336.
31. Lee EJ, Woo MS, Moon PG, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010;185:615-623.
32. Gure TR, Kabeto MU, Plassman BL, Piette JD, Langa KM. Differences in functional impairment across subtypes of dementia. J Gerontol A Biol Sci Med Sci 2010;65:434-441.
33. Foulds PG, Yokota O, Thurston A, et al. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and dementia with Lewy bodies. Neurobiol Dis 2012;45:188-195.
34. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology 2008;70:2212-2218.
35. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010;75:1786-1793.
36. Vos PE, Lamers KJ, Hendriks JC, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62:1303-1310.
37. Vekrellis K, Stefanis L. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Expert Opin Ther Targets 2012;16:421-432.